Vertex Kidney Drug Hits Phase 3; Lilly's $3B China Expansion; UCB Bimzelx Beats Skyrizi

Vertex cleared Phase 3 in kidney disease last night—after-hours trading says the market believes this is a franchise.

UCB just handed AbbVie another head-to-head loss, Lilly's betting three billion on China, and the FDA approved a drug for fewer than fifty patients worldwide. Wednesday's moving fast.

Welcome to The Pharma Closeout for Wednesday, March 11th, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's get to work.

Vertex delivered last night. Phase 3 data for their kidney disease program hit the primary endpoint, and the stock responded—shares surged in after-market trading. This is the asset they acquired in a multibillion-dollar deal, and they've been calling it best-in-class potential since day one.

Best-in-class is easy to say. The question is whether the effect size justifies that positioning. Kidney disease is crowded now—multiple late-stage programs, several mechanisms. Meeting a primary endpoint gets you into the conversation. It doesn't win it.

Fair. But here's why this matters strategically: Vertex built everything on cystic fibrosis. Trikafta is extraordinary, but it's one franchise. They've been telegraphing diversification for years, and this kidney program was the clearest signal they meant it. Last night validates the thesis.

It validates that the drug works. Whether it works well enough to carve out share against entrenched competitors—that depends on durability data, the safety profile, and what the label looks like. If there are renal function cutoffs or patient selection caveats, the commercial story narrows fast.

The after-hours move tells you investors were waiting for this. They needed confirmation that the acquisition wasn't just a press release. Now the calculus shifts to regulatory timeline. How quickly can Vertex file? How aggressively will they pursue a broad label?

And whether the competitive programs stumble. Vertex isn't operating in a vacuum. If one of the other late-stage kidney assets hits a safety signal or misses an endpoint, the runway extends. If they all succeed, this becomes a market share fight on price and access.

For anyone tracking nephrology—Vertex just went from theoretical entrant to credible threat. The board changed last night.

Staying with big moves—Eli Lilly announced a three-billion-dollar manufacturing expansion in China this morning, plus another five hundred million committed to South Korea.

The China investment is specifically for GLP-1 pill production. They're not building generalist capacity—they're scaling oral obesity and diabetes manufacturing where demand is accelerating fastest.

Lilly's trading just under a thousand dollars a share, down about seven percent year-to-date despite the franchise strength. Market cap approaching nine hundred billion. This is a company that touched the trillion-dollar club and is now spending to stay there.

The timing says something. Most pharma guidance for 2026 is signaling deceleration. Lilly's doubling down on production while everyone else manages expectations. That's either confidence or hubris—probably confidence given the demand curves.

Two quick pipeline hits. Bristol Myers posted positive data for mezigdomide in multiple myeloma—that's the next-gen CELMoD they need to backstop the Revlimid cliff. And Xenon Pharmaceuticals jumped roughly fifty percent on epilepsy data. Fifty percent in a day.

That kind of move means the mechanism was genuinely derisked. The market was discounting the probability of success, and the data said otherwise.

And a leadership story worth flagging: BioNTech co-founders Ugur Sahin and Özlem Türeci are stepping down to launch a new mRNA discovery startup. The architects of the COVID vaccine are going back to early-stage science.

That's either the natural arc of founders who want to build again, or a signal about where BioNTech's headed without them. The mRNA platform space just got a new entrant with unmatched credibility.

On the regulatory side—an unusual approval today. The FDA cleared GSK's leucovorin for cerebral folate deficiency. This is a decades-old drug repurposed for an ultra-rare brain disease affecting fewer than fifty documented patients worldwide.

And here's the tension. The Trump administration initially framed this regulatory push as potentially helping hundreds of thousands of children with autism. The actual indication is orders of magnitude narrower.

Cerebral folate deficiency is real, and these patients deserve treatment options. But the gap between the political messaging and the clinical reality is striking. You don't build a commercial model on fifty patients. You don't measure public health impact in dozens.

This is worth watching as a template. When indication scope and public framing diverge this sharply, it raises questions about how regulatory priorities get set—and who they're actually serving.

Also today—Roche's giredestrant failed in breast cancer. Another oral SERD that couldn't clear the bar in the ER-positive setting.

The oral SERD thesis keeps looking better on paper than in trials. Roche isn't the first to stumble here. The mechanism makes sense; the clinical execution keeps proving harder than expected.

GSK's linerixibat has a PDUFA on March 24th for cholestatic pruritus—that's the next decision that moves a market. Liver disease with real unmet need, and a binary outcome in two weeks.

Two threads to follow. First, that UCB-Skyrizi head-to-head we mentioned up top—Bimzelx beat Skyrizi in psoriatic arthritis and stays undefeated in direct comparisons. AbbVie's going to have to respond, and how they respond shapes the competitive narrative for the rest of the year.

When you're undefeated in head-to-heads, your commercial team starts leading with that message. AbbVie's Skyrizi is a blockbuster—they won't cede positioning quietly.

Second, the FDA leadership picture. Dr. Prasad's exit is official, and gene therapy stocks rallied on the news. The market's pricing in expectations about what changes at the agency. Whether those expectations are right—we'll know soon enough.

That's your Pharma Closeout for Wednesday, March 11th—Vertex proving the kidney bet was real, Lilly going big in China, UCB staying undefeated, and the FDA navigating some very public contradictions. This industry keeps delivering. If you want to stay across it, subscribe wherever you listen and drop us a rating—it helps. We're back tomorrow.

Go enjoy your evening. See you then. ## EPISODE METADATA **Title:** Vertex Kidney Drug Hits Phase 3; Lilly's $3B China Expansion; UCB Bimzelx Beats Skyrizi | Mar 11, 2026 **Description:** Vertex clears Phase 3 in kidney disease as after-hours shares surge. Plus Lilly commits $3B to China GLP-1 manufacturing, UCB's Bimzelx defeats AbbVie's Skyrizi head-to-head, and an FDA approval for fewer than 50 patients worldwide. Wednesday's essential pharma intelligence. **Tags:** Vertex, kidney disease, Eli Lilly, China manufacturing, GLP-1, UCB, Bimzelx, AbbVie, Skyrizi, psoriatic arthritis, GSK, leucovorin, cerebral folate deficiency, Bristol Myers, mezigdomide, multiple myeloma, Xenon, epilepsy, BioNTech, mRNA, Roche, giredestrant, FDA, clinical trials, pharma, pharmaceutical, biotech, drug approvals #